ArticleCell biochemistry and biophysics2025
Computational Identification and Validation of Metabolic Cell Death-Related Prognostic Biomarkers for Personalized Treatment Strategies in Prostate Cancer.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Prostate cancer (PCa) is a prevalent malignancy characterized by metabolic dysregulation and varied prognosis. Identifying prognostic biomarkers related to metabolic cell death could enhance risk stratification and treatment strategies. The purpose of this study was to identify prognostic genes associated with metabolic cell death in PCa and formulate a risk model for improved patient stratification. We identified genes that exhibit differential expression in The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) cohort (n = 394), with validation using GSE70769 (n = 92) and RT-qPCR on tissue samples from 5 patients. Candidate genes were intersected with metabolic cell death-related genes to identify prognostic markers. Independent prognostic factors were determined utilizing univariate and multivariate Cox regression analyses (p < 0.05, HR ≠ 1). A nomogram was designed, and the validation of gene expression was carried out using RT-qPCR on tissue samples from five PCa patients. A total of 78 candidate genes were identified, with ASNS and ZNF419 emerging as independent prognostic factors. The gene-based risk model successfully stratified patients into high- and low-risk groups, demonstrating correlations with overall survival and clinicopathological features, while also revealing significant differences in immune cell infiltration patterns through immune microenvironment analysis. Additionally, somatic mutation analysis indicated TP53, TTN, and SPOP as frequently mutated genes. This study identifies ASNS and ZNF419 as novel prognostic biomarkers in PCa, contributing to improved risk stratification and personalized treatment strategies. Further investigation into their functional roles may provide insights into therapeutic targets for PCa management.
Indexed as
Identifiers
40210782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.